L Aldred, MD
Pulmonary Disease · Hattiesburg, MSNPI 1720428121
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (47.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Intuitive Surgical at 53.8% of the total. 2025 is the largest year on record at $60,841, more than ten times the $779 reported in 2019. Among pulmonary disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 607 payments — averaging $125.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$41K
- GSK$27K
- AstraZeneca$1K
- Johnson & Johnson$1K
- Mylan Specialty L.p.$819
- Boehringer Ingelheim$565
- plus $5K from 42 others
What the payments were for
- Speaking & faculty fees$23,75031%
- Travel & lodging$4,4516%
- Food & beverage$11,90616%
- Education$36,02547%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$40,492
- NUCALA$24,438
- Monarch Platform$1,033
- TRELEGY ELLIPTA$123
- TEZSPIRE$107
- BREZTRI$107
- FASENRA$107
How this compares
$76,132 in reported general payments places this provider in the 95th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 33 | $419,992 |
| OfevNintedanib Esylate | 31 | $397,382 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 401 | $306,485 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 25 | $296,680 |
| AdempasRiociguat | 12 | $162,687 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 180 | $138,286 |
| Ambrisentan | 18 | $89,856 |
| Breo ElliptaFluticasone/Vilanterol | 165 | $74,842 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 123 | $66,932 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 101 | $55,047 |
| Dupixent PenDupilumab | 13 | $48,646 |
| Spiriva RespimatTiotropium Bromide | 55 | $45,665 |
| TezspireTezepelumab-Ekko | 11 | $42,682 |
| SymbicortBudesonide/Formoterol Fumarate | 119 | $40,594 |
| Advair HfaFluticasone Propion/Salmeterol | 94 | $33,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $565 | $522,383234 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $26,516 | $453,757712 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $352 | $419,99233 claims |
| Grifols USA, LLCProlastin C | $521 | $296,68025 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $1,348 | $237,068346 claims |
| BayerAdempas | $187 | $162,68712 claims |
| PfizerEliquis | $175 | $26,82547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Hattiesburg
- Walid YounisHattiesburg$15K
- Tamer HudaliHattiesburg$15K
- Michael RaggioHattiesburg$11K
- Lewis NeeseHattiesburg$9K
- Kevin KinlochHattiesburg$6K
- Randolph RossHattiesburg$5K
- Charles McCollumHattiesburg$4K
- Andrew RognessHattiesburg$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.